Motixafortide
Metastatic Pancreatic Cancer (1st line)
Key Facts
About BioLineRx
BioLineRx is a publicly traded, Israeli biotech company with a mission to develop best-in-class therapies for oncology and rare diseases. Its core strategy involves in-licensing and advancing novel drug candidates through clinical proof-of-concept, exemplified by the successful FDA approval and out-licensing of its stem cell mobilizer, motixafortide (APHEXDA®). The company has now pivoted back to a lean development model, focusing its resources on a promising new joint venture for GLIX1 in glioblastoma and a partnered Phase 2b trial in pancreatic cancer.
View full company profileAbout BioLineRx
BioLineRx is a publicly traded, Israeli biotech company with a mission to develop best-in-class therapies for oncology and rare diseases. Its core strategy involves in-licensing and advancing novel drug candidates through clinical proof-of-concept, exemplified by the successful FDA approval and out-licensing of its stem cell mobilizer, motixafortide (APHEXDA®). The company has now pivoted back to a lean development model, focusing its resources on a promising new joint venture for GLIX1 in glioblastoma and a partnered Phase 2b trial in pancreatic cancer.
View full company profileAbout BioLineRx
BioLineRx is a publicly traded, Israeli biotech company with a mission to develop best-in-class therapies for oncology and rare diseases. Its core strategy involves in-licensing and advancing novel drug candidates through clinical proof-of-concept, exemplified by the successful FDA approval and out-licensing of its stem cell mobilizer, motixafortide (APHEXDA®). The company has now pivoted back to a lean development model, focusing its resources on a promising new joint venture for GLIX1 in glioblastoma and a partnered Phase 2b trial in pancreatic cancer.
View full company profile